Inotek Pharmaceuticals Initiates Dosing of MATRx-1, the First Pivotal Phase 3 Clinical Trial of Trabodenoson, a Novel Treatment for Glaucoma

LEXINGTON, Mass.--(BUSINESS WIRE)--Inotek Pharmaceuticals Initiates Dosing of MATRx- 1, the First Pivotal Phase 3 Clinical Trial of Trabodenoson, a Novel Treatment for Glaucoma

Full Story →